Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83

Effects of lycopene on protein expression in human primary prostatic epithelial cells. Cancer Prev Res (Phila) (2013) 1.53

Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer (2015) 1.39

Skp2: a novel potential therapeutic target for prostate cancer. Biochim Biophys Acta (2011) 1.21

The omega-3 polyunsaturated fatty acid DHA induces simultaneous apoptosis and autophagy via mitochondrial ROS-mediated Akt-mTOR signaling in prostate cancer cells expressing mutant p53. Biomed Res Int (2013) 1.07

Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci (2014) 1.07

Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis (2014) 1.03

Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea. J Nutr Biochem (2013) 1.02

Dietary protein restriction inhibits tumor growth in human xenograft models. Oncotarget (2013) 1.02

The phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activation. J Biol Chem (2014) 1.02

Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am (2010) 1.02

Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications. World J Virol (2012) 0.98

Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. Prostate Cancer (2013) 0.94

The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1. PLoS One (2013) 0.93

Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Mol Cancer Res (2011) 0.93

Omega-3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells. J Pharmacol Exp Ther (2014) 0.91

Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells. RSC Adv (2014) 0.90

New hormonal therapies for castration-resistant prostate cancer. Endocrinol Metab Clin North Am (2011) 0.90

Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment. Cancer Biol Ther (2013) 0.89

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer (2011) 0.89

mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocr Relat Cancer (2012) 0.89

Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1. J Biol Chem (2012) 0.87

Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells. Br J Cancer (2012) 0.87

Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug. J Med Chem (2012) 0.85

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives. Cancers (Basel) (2011) 0.85

Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist (2011) 0.85

Alisol B acetate induces apoptosis of SGC7901 cells via mitochondrial and phosphatidylinositol 3-kinases/Akt signaling pathways. World J Gastroenterol (2009) 0.84

AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation. Am J Cancer Res (2015) 0.84

Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells. PLoS One (2013) 0.83

Antitumor effect of Kanglaite® injection in human pancreatic cancer xenografts. BMC Complement Altern Med (2014) 0.83

Therapeutic potential of mTOR inhibitors for targeting cancer stem cells. Br J Clin Pharmacol (2015) 0.82

Astrocyte elevated gene-1 mediates glycolysis and tumorigenesis in colorectal carcinoma cells via AMPK signaling. Mediators Inflamm (2014) 0.82

Prostate cancer: the need for biomarkers and new therapeutic targets. J Zhejiang Univ Sci B (2014) 0.82

Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells. Mol Biol Cell (2015) 0.82

Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy. Future Oncol (2010) 0.82

Castration-resistant prostate cancer: potential targets and therapies. Biologics (2012) 0.81

Alternative splicing programs in prostate cancer. Int J Cell Biol (2013) 0.81

Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia (2013) 0.81

Phytochemicals from cruciferous vegetables, epigenetics, and prostate cancer prevention. AAPS J (2013) 0.81

Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth. PLoS One (2015) 0.81

The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer. Nutr Metab (Lond) (2012) 0.81

Novel targets for prostate cancer chemoprevention. Endocr Relat Cancer (2010) 0.80

Caffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signaling. Int J Mol Sci (2013) 0.80

Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death. Cell Death Dis (2014) 0.80

PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability. Oncotarget (2015) 0.80

Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements. Oncoscience (2015) 0.79

High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer. Oxid Med Cell Longev (2015) 0.79

Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J Nutr Biochem (2015) 0.79

Transcription factor and microRNA-regulated network motifs for cancer and signal transduction networks. BMC Syst Biol (2015) 0.79

Intrinsic and Tumor Microenvironment-Induced Metabolism Adaptations of T Cells and Impact on Their Differentiation and Function. Front Immunol (2016) 0.78

Interleukin-2 Receptor β Thr-450 Phosphorylation Is a Positive Regulator for Receptor Complex Stability and Activation of Signaling Molecules. J Biol Chem (2015) 0.78

Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats. J Cell Mol Med (2016) 0.77

Arctigenin in combination with quercetin synergistically enhances the antiproliferative effect in prostate cancer cells. Mol Nutr Food Res (2014) 0.77

Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer. Oncotarget (2015) 0.77

Prostate cancer and the unfolded protein response. Oncotarget (2016) 0.77

Reduction of insulin signalling pathway IRS-1/IRS-2/AKT/mTOR and decrease of epithelial cell proliferation in the prostate of glucocorticoid-treated rats. Int J Exp Pathol (2012) 0.76

Roles of sex-determining region Y-box 2 in cell pluripotency and tumor-related signaling pathways. Mol Clin Oncol (2015) 0.76

Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia. Mol Cancer (2013) 0.76

Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice. Oncotarget (2015) 0.76

Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int (2015) 0.76

A Comprehensive and System Review for the Pharmacological Mechanism of Action of Rhein, an Active Anthraquinone Ingredient. Front Pharmacol (2016) 0.76

Subpathway-LNCE: Identify dysfunctional subpathways competitively regulated by lncRNAs through integrating lncRNA-mRNA expression profile and pathway topologies. Oncotarget (2016) 0.75

Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer. PLoS One (2017) 0.75

Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo". Oncotarget (2016) 0.75

The role of chemotherapy and new targeted agents in the management of primary prostate cancer. J Clin Urol (2016) 0.75

Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer. Oncotarget (2016) 0.75

The Synthetic β-Nitrostyrene Derivative CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis via PI3K/AKT and STAT3 Pathways. PLoS One (2016) 0.75

Microtubule-associated protein tau is associated with the resistance to docetaxel in prostate cancer cell lines. Res Rep Urol (2017) 0.75

ER stress and impaired autophagy flux in neuronal degeneration and brain injury. Ageing Res Rev (2016) 0.75

Anti-cancer and Sensibilisation Effect of Triptolide on Human Epithelial Ovarian Cancer. J Cancer (2016) 0.75

Alisol A 24-Acetate and Alisol B 23-Acetate Induced Autophagy Mediates Apoptosis and Nephrotoxicity in Human Renal Proximal Tubular Cells. Front Pharmacol (2017) 0.75

Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer. Oncotarget (2016) 0.75

Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44

Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57

Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A (1999) 11.38

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02

Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol (1998) 6.27

Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J (1996) 6.08

Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol (2008) 5.98

Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J (1997) 5.57

The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol (2004) 5.43

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol (2002) 5.39

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol (2008) 5.28

Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res (2006) 4.86

Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol (2004) 4.67

The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem (1999) 4.62

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) (1975) 4.37

Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta (2007) 3.69

Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res (2003) 3.52

Akt-regulated pathways in prostate cancer. Oncogene (2005) 3.35

Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res (1999) 3.29

Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res (1994) 3.22

Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17

The target of rapamycin (TOR) proteins. Proc Natl Acad Sci U S A (2001) 3.16

High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res (2004) 2.75

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol (2008) 2.65

Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev (2005) 2.56

Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res (2006) 2.46

Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res (2002) 2.46

Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A (2001) 2.45

p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem (2000) 2.31

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol (2006) 2.29

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem (2000) 2.28

HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res (2000) 2.25

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther (2003) 2.24

Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res (2006) 2.21

Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res (2004) 2.15

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res (2008) 2.15

Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer (2007) 2.00

Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem (2003) 1.90

Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol (2003) 1.89

Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun (2003) 1.82

Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res (2002) 1.79

The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J Biol Chem (2002) 1.77

Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol (2002) 1.77

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res (2006) 1.75

Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res (2003) 1.69

Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys (2003) 1.68

Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res (2002) 1.67

Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res (2007) 1.66

The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res (1999) 1.64

Signal transduction in prostate cancer progression. Clin Sci (Lond) (2005) 1.64

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res (2008) 1.63

Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer (2007) 1.60

Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res (2007) 1.60

PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal (2007) 1.58

Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res (2007) 1.58

Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate (2006) 1.57

Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res (2008) 1.57

Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res (1995) 1.57

Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res (2007) 1.57

Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol (1999) 1.56

Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res (2005) 1.55

The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis (2005) 1.53

Molecular markers of prostate cancer outcome. Eur J Cancer (2005) 1.52

Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res (2005) 1.48

Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol (2002) 1.48

Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer (2006) 1.47

Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem (2005) 1.46

Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer (2005) 1.43

Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer (2005) 1.42

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int (2005) 1.40

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther (2008) 1.38

Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res (2006) 1.37

Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol (2004) 1.34

Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer. Int J Cancer (2003) 1.34

Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets (2007) 1.34

Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res (2003) 1.34

3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res (2004) 1.33

Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.31

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res (2008) 1.31

Androgen receptor cross-talk with cell signalling pathways. Growth Factors (2004) 1.31

Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin. Cancer Res (2005) 1.31

Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1). Cell Cycle (2007) 1.30

Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther (2004) 1.30

Mechanisms of resistance to rapamycins. Drug Resist Updat (2001) 1.28

Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst (2007) 1.27

Murine prostate cancer inhibition by dietary phytochemicals--curcumin and phenyethylisothiocyanate. Pharm Res (2008) 1.27

Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res (2006) 2.69

Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med (2007) 2.20

Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis (2007) 1.41

Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol (2011) 1.33

Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate (2003) 1.30

Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis (2008) 1.25

Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer (2006) 1.23

Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer (2003) 1.18

Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate (2009) 1.14

Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci (2007) 1.10

RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate (2008) 1.09

Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. J Bone Miner Res (2013) 1.07

Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res (2006) 1.06

Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia (2010) 1.06

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One (2013) 1.03

Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia (2006) 1.02

Metastases of prostate cancer express estrogen receptor-beta. Urology (2004) 1.01

The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate (2010) 0.96

Characterization of C4-2 prostate cancer bone metastases and their response to castration. J Bone Miner Res (2003) 0.95

When prostate cancer meets bone: control by wnts. Cancer Lett (2007) 0.95

Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat Res (2004) 0.93

Role of WNT7B-induced noncanonical pathway in advanced prostate cancer. Mol Cancer Res (2013) 0.93

Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia. Int J Cancer (2003) 0.91

Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases. BMC Cancer (2007) 0.90

Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Mod Pathol (2013) 0.90

Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate (2013) 0.89

Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate (2010) 0.89

HE3235 inhibits growth of castration-resistant prostate cancer. Neoplasia (2009) 0.87

Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment. Clin Exp Metastasis (2013) 0.83

Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer. BMC Cancer (2010) 0.82

Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. Prostate (2014) 0.82

Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. Int J Cancer (2006) 0.81

Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone. Int J Mol Sci (2013) 0.80

Bone morphogenetic proteins and prostate cancer: evolving complexities. J Urol (2007) 0.79

Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Mol Cancer (2010) 0.78

Methodology to investigate androgen-sensitive and castration-resistant human prostate cancer xenografts in preclinical setting. Methods Mol Biol (2011) 0.76

Low dose, alternating electric current inhibits growth of prostate cancer. Prostate (2010) 0.75